Clincosm LogoSign in Get a demo

Neoadjuvant Therapy

Showing 1 - 25 of 66
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cadonilimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy Trial in Guangzhou (Cadonilimab Combined With Lenvatinib)

Recruiting
  • Cadonilimab
  • +2 more
  • Cadonilimab Combined With Lenvatinib
  • Guangzhou, Other (Non U.s.), China
    Sun Yat-sen University Cancer Center
Nov 16, 2023

Colonic Tumors, Neoadjuvant Therapy, Immune Checkpoint Inhibitors Trial in Nanning (Tislelizumab, Oxaliplatin, Capecitabine)

Recruiting
  • Colonic Neoplasms
  • +2 more
  • Nanning, Guangxi, China
    The First Affiliated Hospital of Guangxi Medical University
Nov 9, 2023

Head and Neck Squamous-cell Carcinoma

Not yet recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • +2 more
    • (no location specified)
    Nov 5, 2023

    Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab Trial in Beijing (Pembrolizumab, Cisplatin,

    Recruiting
    • Head and Neck Squamous Cell Carcinoma
    • +2 more
    • Beijing, Beijing, China
      Beijing Tongren Hospital
    Oct 26, 2023

    NSCLC, Neoadjuvant Therapy, Radiotherapy Trial in Yangzhou (drug, radiation, other)

    Recruiting
    • Non-small Cell Lung Cancer
    • +3 more
    • Yangzhou, Jiangsu, China
      People's hospital of northern jiangsu
    Sep 26, 2023

    Colon Cancer, Neoadjuvant Therapy, Immunotherapy Trial in Guangzhou (Envafolimab, CAPEOX)

    Recruiting
    • Colon Cancer
    • +2 more
    • Guangzhou, Guangdong, China
      Sun Yat-Sen University Cancer Center
    Aug 26, 2023

    Esophageal Carcinoma, Neoadjuvant Therapy Trial (Toripalimab, Anlotinib HCl, Albumin paclitaxel)

    Not yet recruiting
    • Esophageal Carcinoma
    • Neoadjuvant Therapy
    • (no location specified)
    Aug 16, 2023

    Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy Trial in Wuhan (drug, procedure, radiation)

    Not yet recruiting
    • Head and Neck Squamous Cell Carcinoma
    • Neoadjuvant Therapy
    • 3cycles (Toripalimab + cetuximab)
    • +2 more
    • Wuhan, Hebei, China
      Union Hospital, Tongji Medical College, Huazhong University of S
    Aug 6, 2023

    Breast Cancer, Neoadjuvant Therapy Trial in Beijing (Utidelone, Carboplatin, Epirubicin)

    Not yet recruiting
    • Breast Cancer
    • Neoadjuvant Therapy
    • Beijing, Beijing, China
      Cancer Hospital, Chinese Academy of Medical Sciences
    Aug 1, 2023

    Head and Neck Squamous Cell Carcinoma, Magnetic Resonance Imaging, Neoadjuvant Therapy Trial in Guangzhou

    Recruiting
    • Head and Neck Squamous Cell Carcinoma
    • +2 more
      • Guangzhou, Guangdong, China
        Sun Yat-sen Memorial Hospital
      Jul 27, 2023

      Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in ZhengZhou (Cadonilimab

      Not yet recruiting
      • Colorectal Cancer
      • +3 more
      • Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
      • ZhengZhou, Henan, China
        Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
      Jun 18, 2023

      COGNITION: Genomics-Guided Precision Oncology in Early High-Risk

      Recruiting
      • Early-Stage Breast Cancer
      • Neoadjuvant Therapy
      • Genomic Profiling / Sequencing
      • Berlin, Germany
      • +4 more
      Jun 19, 2023

      NSCLC, Neoadjuvant Therapy Trial in Hangzhou (Serplulimab and neoadjuvant therapy, surgical resection of lung cancer)

      Recruiting
      • NSCLC
      • Neoadjuvant Therapy
      • Serplulimab and neoadjuvant therapy
      • surgical resection of lung cancer
      • Hangzhou, China
        2nd Affiliated Hospital, School of Medicine, Zhejiang University
      May 22, 2023

      Breast Cancer, Neoadjuvant Therapy Trial in Wuhan (Disitamab Vedotin combined with Tislelizumab)

      Recruiting
      • Breast Cancer
      • Neoadjuvant Therapy
      • Disitamab Vedotin combined with Tislelizumab
      • Wuhan, Hubei, China
        WuhanHU
      May 16, 2023

      Resectable Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy Trial (cadonilimab+chemo)

      Not yet recruiting
      • Resectable Esophageal Squamous Cell Carcinoma
      • Neoadjuvant Therapy
      • (no location specified)
      Apr 18, 2023

      NSCLC, Stage II-IIIA, Immunotherapy Trial in Shanghai (Serplulimab and Chemotherapy)

      Recruiting
      • Non-small Cell Lung Cancer
      • +3 more
      • Serplulimab and Chemotherapy
      • Shanghai, Shanghai, China
        Fudan University Shanghai Cancer Center
      Mar 27, 2023

      Colon Cancer, Neoadjuvant Therapy Trial in Hangzhou (Camrelizumab , apatinib and chemo)

      Recruiting
      • Colon Cancer
      • Neoadjuvant Therapy
      • Camrelizumab , apatinib and chemotherapy
      • Hangzhou, Zhejiang, China
        First affiliated hospital, Zhejiang University
      Jan 27, 2023

      Neoadjuvant Therapy Trial in Nanjing (pamiparib, abiraterone, prednisone)

      Recruiting
      • Neoadjuvant Therapy
      • Nanjing, Jiangsu, China
      • +2 more
      Jan 3, 2023

      Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy Trial in Hangzhou (Serplulimab, Albumin paclitaxel, carboplatin AUC=5,

      Recruiting
      • Esophageal Squamous Cell Carcinoma
      • Neoadjuvant Therapy
      • Serplulimab, Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy
      • Esophagectomy
      • Hangzhou, China
        2nd Affiliated Hospital, School of Medicine, Zhejiang University
      Dec 20, 2022

      HER2-negative Breast Cancer, Neoadjuvant Therapy, Pathological Complete Response Trial in Beijing (Camrelizumab with vinorelbine

      Recruiting
      • HER2-negative Breast Cancer
      • +5 more
      • Camrelizumab with vinorelbine and cisplatin
      • Beijing, Beijing, China
        Peking University First Hospital
      Oct 15, 2022

      High-risk Prostate Cancer, Neoadjuvant Therapy Trial in Shanghai (Abiraterone acetate, Fluzoparib, Prednisone)

      Recruiting
      • High-risk Prostate Cancer
      • Neoadjuvant Therapy
      • Abiraterone acetate
      • +4 more
      • Shanghai, Shanghai, China
        Fudan University Shanghai Cancer Center
      Oct 6, 2022

      Breast Cancer, Neoadjuvant Therapy, Sentinel Lymph Node Biopsy Trial in Fuzhou (carbon dye)

      Recruiting
      • Breast Cancer
      • +2 more
      • carbon dye
      • Fuzhou, Fujian, China
        Study Officials
      Aug 22, 2022

      Neoadjuvant Therapy, High Risk Prostate Cancer, Locally Advanced Prostate Cancer Trial in Nanjing (ADT, Abiraterone Acetate,

      Recruiting
      • Neoadjuvant Therapy
      • +3 more
      • Nanjing, Jiangsu, China
        Department of Urology, Drum Tower Hospital, Medical School of Na
      Aug 12, 2022

      Squamous Cell Carcinoma of Head and Neck, Neoadjuvant Therapy, Resection Margin Trial in Wuhan (Reducing Excision Margins)

      Active, not recruiting
      • Squamous Cell Carcinoma of Head and Neck
      • +2 more
      • Reducing Excision Margins
      • Wuhan, Hubei, China
        Zhanjie Zhang
      Jul 11, 2022

      Postoperative Radiotherapy for Oral Squamous Cell Carcinoma

      Recruiting
      • Radiotherapy
      • +3 more
        • Shanghai, Shanghai, China
          Ninth People's Hospital, Shanghai Jiao Tong University School of
        Jul 12, 2022